![Johnson & Johnson eyes $2.5B in COVID vaccine sales as key immunology, oncology meds trounce expectations | Fierce Pharma Johnson & Johnson eyes $2.5B in COVID vaccine sales as key immunology, oncology meds trounce expectations | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1626880773/JNJIOffice3.jpg/JNJIOffice3.jpg?VersionId=J86xnnQ5N21hBBHQIqg5T5gAXTYCg4Ln)
Johnson & Johnson eyes $2.5B in COVID vaccine sales as key immunology, oncology meds trounce expectations | Fierce Pharma
![FDA expands recall of blood pressure drug valsartan due to cancer concern | <span class="tnt-section-tag no-link">News</span> | WPSD Local 6 FDA expands recall of blood pressure drug valsartan due to cancer concern | <span class="tnt-section-tag no-link">News</span> | WPSD Local 6](https://bloximages.newyork1.vip.townnews.com/wpsdlocal6.com/content/tncms/assets/v3/editorial/b/58/b5800939-e466-5ae7-8768-28627ced7964/5d419b995657e.image.jpg?resize=1200%2C675)
FDA expands recall of blood pressure drug valsartan due to cancer concern | <span class="tnt-section-tag no-link">News</span> | WPSD Local 6
![May's top stories: Thermo Fisher Scientific buys Patheon for $7.2bn, AstraZeneca to sell rights for Seloken - Pharmaceutical Technology May's top stories: Thermo Fisher Scientific buys Patheon for $7.2bn, AstraZeneca to sell rights for Seloken - Pharmaceutical Technology](https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2017/09/main-1207.jpg)